Durvalumab Improves Survival in Stage III NSCLC
Durvalumab significantly improved overall survival versus placebo when used as a sequential treatment in patients with locally-advanced, unresectable non–small cell lung cancer who had not progressed following standard chemoradiotherapy, according to updated findings from the phase III PACIFIC trial.
Source: OncLive